Last updated: July 30, 2026
Executive summary: In IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00555 (D. Del.), IBSA accused Teva of patent infringement tied to Teva’s FDA generic submission and/or market entry strategy. The case is filed as a patent infringement action in the Hatch-Waxman framework and is centrally focused on Orange Book-listed IP for IBSA’s branded product, with litigation outcomes and any settlement terms determining the timing and scope of Teva’s ability to launch. This dispute is part of IBSA’s enforcement program against a Teva generic strategy and is assessed primarily through (1) the asserted patents and claims, (2) the Paragraph IV landscape, (3) claim construction and validity/infringement rulings, and (4) any court-ordered or settlement-driven launch restrictions.
What patents were asserted in IBSA Institut Biochimique v. Teva (1:18-cv-00555)?
A litigation summary requires the asserted-patent list and the specific claim numbers and theories (infringement, invalidity, unenforceability). That information is not provided in the input, and without it a complete and accurate patent-by-patent analysis cannot be produced.
Which Orange Book patents typically anchor these IBSA vs Teva actions?
Hatch-Waxman cases like this generally assert one or more of the following categories tied to the NDA-listed reference product:
- Composition-of-matter patents on the active ingredient or stereochemical forms
- Formulation or dosage-form patents (excipients, particle size, release profile)
- Method-of-use patents (indications, dosing regimens)
- Manufacturing method patents
- Device or delivery system patents, if the product uses a specific delivery mechanism
What infringement theories are usually pled in this fact pattern?
In Paragraph IV challenges, infringement pleadings often map to:
- Teva’s ANDA formulation (composition and process)
- Product labeling and intended use (method-of-use claims)
- Comparative testing or equivalence arguments used to align ANDA product with asserted claims
When did IBSA sue Teva in 1:18-cv-00555, and what procedural milestones matter?
Timing is decisive for damages exposure, injunction leverage, and launch sequencing. The input does not include the complaint filing date, answer date, amended pleadings, claim construction schedule, expert report deadlines, summary judgment dates, or the final dispositive outcome. Those details are required for a litigation-grade timeline.
Key milestones professionals track in Hatch-Waxman patent cases
A D. Del. Hatch-Waxman docket usually turns on:
- Complaint filing and service
- Teva’s answer and defenses (invalidity, non-infringement, unenforceability)
- Markman/claim construction order
- Daubert rulings and expert testimony admissibility
- Summary judgment motions on infringement and/or validity
- Final judgment and any appeal posture
- Entry of injunctions, consent judgments, or stipulated launch dates
How did the court rule on infringement and validity in IBSA v. Teva (1:18-cv-00555)?
A rules-and-outcome section must identify:
- The court’s claim construction results
- Which patents were found infringed
- Which patents were found invalid or not infringed
- Any partial wins (e.g., one patent survived, others failed)
- Whether the case ended via settlement vs judgment
No disposition details are included in the input. Without the actual rulings or docket outcome, a precise litigation analysis cannot be completed.
What outcomes change generic entry risk
- Judgment of non-infringement or invalidity: accelerates generic entry
- Judgment of infringement and validity: increases risk of injunction and damages
- Settlement: often includes a licensed launch date, carve-outs, or design-around commitments
- Stipulated dismissal without prejudice or procedural terminations: shifts the decision to settlement documentation
Was this a Paragraph IV ANDA challenge, and what does that mean for exclusivity timing?
For exclusivity and generic-launch planning, you need:
- The ANDA number(s)
- The Orange Book listed patents asserted as the basis for the infringement suit
- The Teva notice of certification type (Paragraph I, II, III, IV)
- The “trigger” date for 30-month stay, if applicable
The input does not include the ANDA number, certification type, or Orange Book context, so the exclusivity timeline cannot be computed.
What professionals infer from Paragraph IV labeling
- Paragraph IV typically targets a specific Orange Book patent listed for the reference product
- If the ANDA is accepted and litigation is timely filed, an automatic 30-month stay can delay FDA approval effective date, subject to earlier court resolution
How strong is the patent estate for IBSA’s product in this case?
A strength assessment requires patent-by-patent specifics:
- Patent assignees and prosecution history
- Claim scope (independent claim breadth and dependent claim restrictions)
- Precedent in related cases (same patents with different ANDAs)
- Claim construction constraints
- Validity findings and prior art landscape
No patent numbers or claim information are provided, so the strength cannot be evaluated in a litigation-credible way.
Patent-estate strength factors to quantify
- Likelihood of infringement under construed claim terms
- Prior art gap (independent claim novelty and non-obviousness)
- Vulnerability to obviousness combinations
- Enforceability risk (inequitable conduct) if raised
- Differences between Teva’s ANDA formulation and the patented examples
What settlements or consent judgments resolved IBSA v. Teva (1:18-cv-00555)?
Settlement analysis requires:
- Date of settlement or docket event (e.g., “stipulation of dismissal”)
- Whether settlement included a license, covenant not to sue, or dismissal conditions
- The agreed launch date or payment terms (if disclosed)
- Design-around restrictions, label restrictions, or manufacturing obligations
None of that information is included.
What FDA status impact does this litigation have for Teva and competing generics?
Regulatory impact depends on:
- Whether Teva’s ANDA was approved or remained stayed
- Whether FDA approval was blocked by the 30-month stay
- Whether the case affected Orange Book patent “carve-outs”
- Whether other applicants could launch “at risk”
No FDA filing/approval milestones are provided.
Orange Book status and “at-risk” launching
In practice, competitors track:
- Whether each asserted patent remained listed through FDA’s patent listing mechanics
- Whether the court’s outcome removed or narrowed the basis for delay
- Whether Teva obtained a settlement allowing launch before ultimate patent expiration
Which companies are potential co-defendants or competitors in the same patent family?
This section requires:
- Other cases involving the same patents (e.g., same asserted IBSA patents in related D. Del. actions)
- The set of ANDA filers targeting the same reference drug
- Any parallel biosimilar or branded enforcement actions (if biologic)
No related case identifiers or competitor list is given.
How could court outcomes in 1:18-cv-00555 affect generic launch scenarios?
Generic-launch scenario planning is a function of:
- Patent survival vs invalidity
- Injunction risk and scope
- Settlement-driven exclusivity carve-outs
- Whether design-around variants exist that avoid asserted claims
Without the final outcome or injunction/settlement terms, launch scenarios cannot be derived accurately.
Common generic-launch decision tree in Hatch-Waxman
- If asserted patents are held invalid or not infringed: ANDA approval proceeds and launch timing accelerates
- If held valid and infringed: launch is blocked or occurs only after authorization or settlement design-around
- If settlement exists: launch occurs under contract terms regardless of later appeals unless terms allow earlier entry
Key Takeaways
- The matter IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00555 (D. Del.) is a Hatch-Waxman-type patent infringement dispute tied to IBSA’s Orange Book-listed intellectual property and Teva’s ANDA strategy.
- A complete litigation summary and patent-by-patent analysis cannot be produced from the provided input because the asserted patent list, docket milestones, court rulings, and any settlement terms are not included.
- For business decisions on licensing, challenge strategy, or investment timing, the decisive next data points are: asserted patent numbers and claims; docket disposition (judgment vs settlement); claim construction outcomes; and any launch date or covenant terms.
FAQs
- What is the docket disposition for IBSA v. Teva (1:18-cv-00555), and did it end in judgment or settlement?
- Which Orange Book patents did IBSA assert against Teva in this case?
- Did the court grant any preliminary injunction or enter any stipulated launch restriction?
- How did claim construction affect infringement analysis for the asserted IBSA patents?
- What was the downstream effect on FDA approval timing for Teva’s ANDA?
References (APA)
- IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc., No. 1:18-cv-00555 (D. Del.).
